期刊
EXPERT OPINION ON THERAPEUTIC TARGETS
卷 24, 期 5, 页码 417-426出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14728222.2020.1743681
关键词
GSK-3; GSK-3 inhibitors; KRas; pancreatic cancer; pancreatic ductal adenocarcinoma; targeted therapy
资金
- Eagles 5th District Cancer Telethon Funds for Cancer Research
- Mayo Clinic Center for Biomedical Discovery
- NCI supported Pancreatic Cancer SPORE grant [CA102701]
Introduction: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the United States with a single-digit 5-year survival rate despite advances in understanding the genetics and biology of the disease. Glycogen synthase kinase-3 alpha (GSK-3 alpha) and GSK-3 beta are serine/threonine kinases that localize to the cytoplasm, mitochondria and nucleus. Although they are highly homologous within their kinase domains and phosphorylate an overlapping set of target proteins, genetic studies have shown that GSK-3 beta regulates the activity of several proteins that promote neoplastic transformation. Significantly, GSK-3 beta is progressively overexpressed during PDAC development where it participates in tumor progression, survival and chemoresistance. Thus, GSK-3 beta has become an attractive target for treating PDAC. Areas covered: This review summarizes the mechanisms regulating GSK-3 beta activity, including upstream translational and post-translational regulation, as well as the downstream targets and their functions in PDAC cell growth, metastasis and chemoresistance. Expert opinion: The activity of GSK-3 kinases are considered cell- and context-specific. In PDAC, oncogenic KRas drives the transcriptional expression of the GSK-3 beta gene, which has been shown to regulate cancer cell proliferation and survival, as well as resistance to chemotherapy. Thus, the combination of GSK-3 inhibitors with chemotherapeutic drugs could be a promising strategy for PDAC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据